Farletuzumab ecteribulin

Farletuzumab ecteribulin is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eisai Inc., in metastatic cancer. An antibody-drug conjugate: an antibody against a tumour surface protein carries a cytotoxic payload into the cell. The registry record does not state the target or payload; the trial entries below carry the sponsor's description. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.